Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PYGL | P06737 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324498 | 0.91 | MEN1 (0.54) | MAPTPOLBPYGLKMT2AMEN1 | |
| SCHEMBL6446057 | 0.86 | ALDH1A1 (0.58) | MAPTPOLBKMT2AMEN1LMNA | |
| SCHEMBL6445774 | 0.83 | PTGER3 (0.54) | MAPTKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL6448596 | 0.82 | SMN1; SMN2 (0.52) | MAPTKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL6445474 | 0.81 | KDM4E (0.53) | MAPTPOLBKMT2AMEN1LMNA | |
| SCHEMBL6445888 | 0.81 | P2RX1 (0.50) | MAPTPOLBKMT2AMEN1LMNA | |
| SCHEMBL6448951 | 0.81 | AKR1C4 (0.48) | MAPTPOLBKMT2AMEN1LMNA | |
| SCHEMBL6444581 | 0.81 | PHGDH (0.56) | MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6447124 | 0.80 | PTGER3 (0.52) | MAPTPOLBKMT2AMEN1LMNA | |
| SCHEMBL6448931 | 0.80 | PTGER3 (0.46) | MAPTKMT2AMEN1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | claimed |
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | MAPT 3346/4885POLB 2892/4885PYGL 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.